相关实验视频
Updated: Jul 19, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
雅努斯酶抑制剂用于白发症
Brett A King1, Brittany G Craiglow1
1Department of Dermatology, Yale School of Medicine, Yale University, New Haven, Connecticut.
Journal of the American Academy of Dermatology
|August 17, 2023
概括
雅努斯酶 (JAK) 抑制剂为形脱发症 (AA) 提供了新的希望. 这些药物有效治疗中度至重度的AA,这种疾病以前对治疗有抗性,这标志着患者护理的重大进步.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 从历史上看,大发性脱发症 (AA) 在中度至重度病例中提供了有限的治疗选择.
- 简氏激酶 (JAK) 抑制剂代表了一种针对自身免疫性疾病的新型治疗类.
研究的目的:
- 审查在AA治疗中使用JAK抑制剂的历史背景和科学理由.
- 总结了AA的JAK抑制剂的第三阶段临床试验的关键发现.
- 讨论临床应用的重要考虑因素,包括药物差异化,安全性概况和患者选择.
主要方法:
- 审查的历史治疗方法治疗白发病的区域性.
- 对Janus激酶 (JAK) 抑制剂的作用机制的分析.
- 来自关键的第三期临床试验的综合数据,研究JAK抑制剂在脱发区域.
- 讨论安全数据和患者分层策略.
主要成果:
- 简氏激酶 (JAK) 抑制剂已在治疗中度至重度脱发区治疗中表现出有效性.
- 临床试验数据支持JAK抑制剂在促进头发再生的有效性.
- 对于区分各种JAK抑制剂和优化患者选择的考虑至关重要.
结论:
- 简氏激酶 (JAK) 抑制剂已经改变了中度至重度脱发区的治疗环境.
- 这些疗法为以前耐火性疾病的患者提供了可行的选择.
- 仔细考虑安全性,疗效和患者特异性因素对于在AA中成功使用JAK抑制剂治疗至关重要.
相关概念视频
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
MAPK Signaling Cascades
5.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K

